TABLE 1

Patient Characteristics

													Time (mos)…
Patient no.	Sex	Age (y)	Tumor origin	Histologic diagnosis	Previous treatment of brain metastasis	No. of PET lesions	Localization	TBR_max	TBR_mean	Pattern of ¹⁸F-FET kinetic	TTP (min)	Histologic diagnosis after PET	Between RT and PET	Of follow-up after PET	Final diagnosis
1	F	45	Breast	DC	WBRT, SRS, OP	1	Left frontal	2.7	1.9	II	20	Yes	10	ND	Met
2	M	58	Lung	NSCLC	OP, SRS	1	L temporal	3.0	1.9	I	25	Yes	19	ND	N
3	F	63	Lung	NSCLC, adenocarcinoma	OP, SRS	1	L frontal	2.5	1.9	I	35	Yes	19	ND	N
4	F	61	Lung	NSCLC	WBRT, SRS	1	L parietal	1.7	1.6	I	30	Yes	9	ND	N
5	F	45	Breast	DC	WBRT, SRS	1	L temporal	2.4	1.7	I	35	Yes	6	ND	N
6	F	69	Breast	DC	SRS	1	L parietal occipital	2.5	1.9	I	35	Yes	60	ND	N
7	F	50	Breast	DC	OP, WBRT, SRS	1	L temporal	3.5	2.1	I	35	Yes	6	ND	Met
8	F	51	Breast	DC	OP, WBRT, SRS	1	R parietal	3.5	2.1	II	20	Yes	10	ND	Met
9	F	17	Bone (pelvis)	Ewing sarcoma	SRS	1	BS	4.1	2.7	III	4	Yes	11	ND	Met
10	F	57	Lung	NSCLC, adenocarcinoma	OP, SRS	1	L parietal	1.5	1.2	I	40	Yes	13	ND	Met
11	F	48	Lung	NSCLC, adenocarcinoma	WBRT	1	L frontal	2.7	2.1	II	20	Yes	11	ND	Met
12	M	50	Skin	MM	SRS	1	L occipital	3.7	2.4	II	17	No	16	Rec	Met
13	F	47	Lung	NSCLC, adenocarcinoma	OP, WBRT, SRS	1	L occipital	3.2	2.1	I	25	No	12	38	N
14	F	69	Lung	NSCLC	SRS	1	R parietal	2.2	1.7	I	40	No	11	7	N
15	F	53	Colon	Adenocarcinoma	OP, WBRT, SRS	1	R parietal	2.2	1.7	I	45	No	10	6	N
16	F	54	Breast	DC	WBRT, SRS	2	L cerebellar (1)	3.5	2.0	II	20	No	11	Rec	Met
							L cerebellar (2)	3.6	2.2	II	20
17	F	64	Lung	SCLC	WBRT, SRS	2	L frontal	2.5	1.9	III	14	No	7	Rec	Met
							BS	2.3	1.8	II	14
18	F	58	Lung	NSCLC, adenocarcinoma	SRS	1	R parietal	2.2	1.8	I	35	No	18	S	N
19	F	43	Lung	NSCLC, adenocarcinoma	OP, SRS	1	L parietal	2.8	2.0	II	11	No	23	Rec	Met
20	F	44	Lung	NSCLC, adenocarcinoma	OP, SRS	1	L parietal	1.8	1.6	I	45	No	11	16	N
21	F	44	Lung	SCLC	WBRT, SRS	1	L parietal occipital	2.4	1.9	I	40	No	23	S	N
22	F	58	Lung	NSCLC	WBRT, SRS	2	R parietal occipital	2.8	2.0	I	35	No	16	Rec	Met
							L temporal	2.4	1.8	II	17
23	M	49	Lung	NSCLC, adenocarcinoma	WBRT, SRS	4	R cerebellar	3.1	1.9	I	40	No	12	S	N
							L frontal	1.9	1.7	I	40
							R parietal occipital	1.8	1.6	I	40
							L parietal occipital	1.6	1.5	I	30
24	F	58	Breast	DC	SRS	1	L parietal	1.8	1.6	I	45	No	32	12	N
25	F	56	Lung	NSCLC	SRS	1	R occipital	2.6	1.8	I	25	No	7	36	N
26	F	58	Lung	SCLC	WBRT, SRS	1	L temporal	2.1	1.9	I	45	No	5	5	N
27	M	33	Skin	MM	OP, WBRT, SRS	3	R parietal occipital	3.7	2.4	III	17	No	4	2^*	Met
							BS	2.6	2.0	II	17
							R parietal	2.6	2.2	II	17
28	F	55	Breast	DC	SRS	1	L parietal	5.8	3.1	II	17	No	NA	1^*	Met
29	F	70	Breast	DC	SRS	1	R occipital	3.6	2.5	II	20	No	15	Rec	Met
30	F	53	Lung	NSCLC, adenocarcinoma	SRS	1	L frontal	2.4	1.9	I	35	No	12	S	N
31	M	53	Kidney	RCC	OP, SRS	2	L occipital	3.0	2.0	I	30	No	15	S	N
							L frontal	2.3	1.7	I	30

↵* Patient died during follow-up.
RT = radiation therapy; DC = ductal carcinoma; OP = resection; ND = not determined; Met = metastasis; NSCLC = non small-cell lung cancer; N = necrosis; BS = brain stem; MM = malignant melanoma; Rec = at time of ¹⁸F-FET PET clinical signs or MRI findings consistent with recurrent metastatic tumor; S = at time of ¹⁸F-FET PET patient stable without new symptoms or MRI findings without signs of tumor progression; SCLC = small cell lung cancer; NA = not available; RCC = renal cell carcinoma;